Scassellati Sforzolini discusses the significance of Galderma’s nemolizumab receiving 4 additional filing acceptances for prurigo nodularis and atopic dermatitis.
It is important dermatologists learn to recognize the clinical findings of dermatophytomas and distinguish them from other onychomycosis subtypes because the recommended treatments differ.
The needs assessment surveyed patients’ stage of treatment, radiation-induced dermatologic adverse effects, and over-the-counter products and home remedies that were used.